Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Manhattan Pharmaceuticals To Focus On Dermatology After Obesity Candidate Fails

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm will discontinue development of oral oleoyl-estrone for obesity after it failed to show a significant difference over placebo in Phase IIa studies.

You may also be interested in...



Manhattan/Nordic Head Lice Therapy Will Be Reviewed As Device

Companies amend February deal that created a joint venture to develop and market Hedrin.

Manhattan/Nordic Head Lice Therapy Will Be Reviewed As Device

Companies amend February deal that created a joint venture to develop and market Hedrin.

Anacor’s Topical Psoriasis Candidate Produces Strong Showing In Phase II

Boron-based anti-inflammatory drug targets TNF-a, other cytokine receptors.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS066293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By